Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2302935 | 1.00 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL6573325 | 1.00 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL2516533 | 0.98 | MAPT (0.40) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL2286672 | 0.98 | MAPT (0.40) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL3637092 | 0.83 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL3634048 | 0.83 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL7208268 | 0.82 | PTGS1 (0.41) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL9680613 | 0.82 | PTGS1 (0.41) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL6573365 | 0.82 | PTGS1 (0.41) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL5341469 | 0.81 | MAPT (0.40) | MAPTCACNA1BAPBA1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907132-B2 | Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2013-02-14 | — | — | US | disclosed |
| EP-2534127-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN Laboratories Limited (IN) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011099033-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-08-18 | — | — | WO | disclosed |
| EP-0680327-B1 | THERAPEUTIC USES AND DELIVERY SYSTEMS OF DEHYDROEPIANDROSTERONE | ENDORECH INC (CA) | 2004-09-15 | — | — | EP | disclosed |
| JP-2004099479-A | 1,3-OXAZOLIDINE-2-THIONE COMPOUND AND METHOD FOR PRODUCING THE COMPOUND AND POLYTHIOURETHANE AND METHOD FOR PRODUCING THE POLYMER | JSR CORP | 2004-04-02 | — | — | JP | disclosed |
| US-5955455-A | SEX STEROID PRECURSORS SUCH AS DEHYDROEPIANDROSTERONE AND DEHYDROEPIANDROSTERONE SULPHATE ARE UTILIZED FOR THE TREATMENT OF VAGINAL ATROPHY, HYPOGONADISM, DIMINISHED LIBIDO, LOSS OF COLLAGEN OR CONNECTIVE TISSUES IN THE SKIN, AND, IN | ENDORECHERCHE, INC. (CA) | 1999-09-21 | — | — | US | disclosed |
| US-5948434-A | ADMINISTERING DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE SULPHATE VIA TRANSDERMAL PATCH | ENDORECHERCHE, INC. (CA) | 1999-09-07 | — | — | US | disclosed |
| US-5922700-A | KIT FOR DRUG DELIVERY OF STEROIDS | ENDORECHERCHE, INC. (CA) | 1999-07-13 | — | — | US | disclosed |
| US-5872114-A | Therapeutic methods and delivery systems utilizing sex steroid precursors | ENDORECHERCHE, INC. (CA) | 1999-02-16 | — | — | US | disclosed |
| US-5843932-A | Therapeutic methods and delivery systems utilizing sex steroid precursors | ENDORCAHERCHE, INC. (CA) | 1998-12-01 | — | — | US | disclosed |
| US-5837700-A | MENOPAUSE | ENDORECHERCHE, INC. (CA) | 1998-11-17 | — | — | US | disclosed |
| US-5824671-A | VAGINAL ATROPHY, HYPOGONADISM AND LOSS OF COLLAGEN OR CONNECTIVE TISSUES | ENDORECHERCHE INC (CA) | 1998-10-20 | — | — | US | disclosed |
| US-5807849-A | INHIBITING URINARY INCONTINENCE | ENDORECHERCHE, INC. (CA) | 1998-09-15 | — | — | US | disclosed |
| US-5798347-A | DEHYDROEPIANDROSTERONE AND DEHYDROEPIANDROSTERONE SULFATE USED FOR INHIBITING PROLIFERATION OF OVARIAN CANCER | ENDORECHERCHE, INC. (CA) | 1998-08-25 | — | — | US | disclosed |
| US-5780460-A | ADMINISTERING DEHYDROEPIANDROSTERONE OR SULFATE TO TREAT MENOPAUSE, VAGINAL ATROPHY, AND OSTEOPOROSIS | ENDOREOHERCHE, INC. (CA) | 1998-07-14 | — | — | US | disclosed |
| US-5776923-A | TREATMENT WITH SEX STEROIDS | ENDORECHERCHE, INC. (CA) | 1998-07-07 | — | — | US | disclosed |
| US-5728688-A | TREATMENT OF MENOPAUSE, VAGINAL ATROPHY, HYPOGONADISM AND DIMINISHED LIBIDO | ENDOREOHERCHE, INC. (CA) | 1998-03-17 | — | — | US | disclosed |
| EP-0680327-A1 | THERAPEUTIC USES AND DELIVERY SYSTEMS OF DEHYDROEPIANDROSTERONE | ENDORECHERCHE INC. (CA) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994016709-A2 | THERAPEUTIC USES AND DELIVERY SYSTEMS OF DEHYDROEPIANDROSTERONE | ENDORECHERCHE INC. (CA) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | AMY1A, PTMA, NAAA | CACNA1B 559/4885MAPT 3463/4885APBA1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.